The 2nd Next Generation RNA Therapeutics Summit returns as the first and only industry-dedicated forum solely focused on next generation RNA therapeutics and vaccines that are more targeted, and efficacious, with reduced off targets than first generation RNA therapies to accelerate their therapeutic and commercial potential.

Expect exclusive data from KOLs on the most recent developments in circRNAs, saRNAs, eRNAs and tRNAs therapies.

Join 100+ thought leaders from the likes of Pfizer, Orna Therapeutics, Laronde, Replicate Bioscience and BioNTech to stay ahead of the curve and maximize the full therapeutic potential of next generation RNA modalities to gain clinical proof concept and reach patients in need.

Read on rna.com

With the recent announcement of Fate Therapeutic's preclinical and clinical success with iPSC-derived candidates, the race to streamline iPSC process development is on.

Join the 2nd iPSC Manufacturing Summit, the industry-defining forum for technical leaders within manufacturing, process development, quality and regulations. Showcasing in-depth data-driven case studies to accelerate the development of high-quality iPSC lines, with optimized differentiation and automated scale up.

This meeting boasts the unique opportunity to discuss the procedural barriers preventing iPSC-derived therapies reaching the clinic, tackling all your CMC and regulatory needs. Take home creative approaches to unify your manufacturing process and advance the quality and quantity of your product for successful commercialization.

Read on summit.com

Uniting leading CMC, Regulatory, QC, Analytical and Process Development experts, the 4th Annual Gene Analytical Development Europe Summit is the industry's definitive and only meeting focused on tackling the greatest analytical development challenges in the context of gene therapy drug development.

Hear from the likes of AstraZeneca, MHRA, Gyroscope, REGENXBIO, Biogen, Spark Therapeutics, and more across three days and two tracks of in-depth case studies, interactive panel discussions, dedicated Q and A time, and highly appraised networking opportunities to meet and learn from the leaders of this pioneering field.

Don't miss the opportunity to network with 80+ analytical experts to overcome your analytical challenges encountered in every stage of the gene therapy development life cycle.

Read on europe.com

From screening technologies directing identification, prediction, and validation of neoantigens; to translating personalised medicine to the clinic, the 6th Annual Neoantigen Summit Europe returns to Amsterdam, as the only summit in Europe dedicated to advancing exclusive tumour antigen discovery and personalised therapeutic development within the world of immunotherapy.

Devoted to the successful discovery, translation, and development of individualised neoantigen vaccines and cell immunotherapies, join 150+ experts at the forum, as they navigate validation of neoantigen targets and review methodologies/technologies to support with translating neoantigen-based studies effectively to the clinic.

Join is in 2023 for the latest preclinical updates, and evaluate the hottest clinical data from leading biotechs, such as Nouscom, Gritstone, and BioNTech, CurVac.

Read on neoantigen-europe.com

Spearheading Safe, Potent, Scalable Innate Immune Therapies Spanning NK, iNKT, Gamma Delta, and Macrophages. Realize Lasting Clinical Response with Next-Generation Engineering to Provide Off-the-Shelf Delivery for More Patients, Globally

Dedicated to driving cost-effective, efficacious, safe, durable, scalable, and globally accessible allogeneic, cell-based, and engager therapies, the 8th Innate Killer Summit returns to cement your end-to-end education in innate immune therapeutics. Your industry-defining Innate Killer Summit brings crucial insights for everyone on your team, spanning preclinical development, clinical translation, CMC, process development, and clinical scale manufacturing, this is the definitive meeting to drive concept to commercial success of emerging innate immune therapies.

Read on innate-killer.com

Welcome to the 4rd Annual RNAi - Based Therapeutics Summit: Unleash the Potential of siRNA Therapies in Extrahepatic Tissues

Bringing together both technical and strategic expertise sharing case studies with actionable insights, the 4th RNAi-Based Therapeutics Summit returns to Boston to address the most pressing challenges preventing the widespread adoption of RNAi therapies and tackling targets beyond the liver.

With 20+ pioneering speakers from large pharma, innovative biotech, and KOLs of academia, join us to discuss novel delivery modalities, next-generation chemistries, clinical updates, scaling up. and more.

Read on rnaibased-therapeutics.com

With strong effectiveness profiles and 20 years of FDA approval, kinase inhibitors have revolutionized oncology treatment. The success of current kinase inhibitor classes is nevertheless constrained by rising resistance and security concerns.

The 2nd Next Generation Kinase Inhibitors Summit is the only industry-focused conference devoted to using novel kinase biology in drug development and innovating current programs to produce the next generation of kinase inhibitor drugs that can demonstrate effective and long-lasting clinical responses in oncology and other fields.

Read on summit.com

The past twelve months have seen an unprecedented level of excitement, investment, and progression within the gene therapy for muscular disorders field. As the industry endeavours to move gene therapy treatment through the preclinical and clinical pipeline, in context of reducing toxicity and increasing efficacy, attending the 3rd Annual Gene Therapy for Muscular Disorders Summit has never been so crucial.

This year's summit will return to Boston to reunite 100+ leading experts in biotech, pharma and academia to continue to develop strategies to deliver safer and more effective gene therapies to muscle cells.

This summit will encompass all aspects of preclinical development and highlight the obstacles in clinical trials, enabling you to address and overcome these challenges.

Read on genetherapy-muscular.com

A high proportion of new drug candidates never reach market due to poor solubility, which limits their potential for absorption. As such, the solubility and permeability of an active pharmaceutical ingredient (API) are the driving forces behind bioavailability. In order to avoid development challenges and delays, it is critical to fully explore these parameters when developing formulations to enhance and maximise oral bioavailability. Lipid-based drug delivery systems offer a way to effectively deliver poorly soluble or bioavailable drugs in both preclinical and human studies. The physicochemical characteristics of the API determine if lipid delivery is an appropriate approach for dosage form design.

Read on xtalks.dryfta.com